Breast cancer is the most common cancer in women worldwide and can be classified into multiple subtypes, including triple-negative breast cancer (TNBC). TNBC is more aggressive than other types of breast cancer and has a poor prognosis. However, excluding chemotherapy, the treatment of TNBC does not involve targeted therapy. The dysregulated expression of lncRNAs plays a vital role in the development of numerous cancers. Thus, the aim of this meta-analysis is to determine the functional roles of lncRNAs in TNBC. We performed a systematic search for articles related to TNBC using multiple online databases, including PubMed, EMBASE, Web of Science, and Science-Direct. We collated pooled hazard ratios with 95% confidence interval to estimate the prognostic value of lncRNAs. We assessed the quality of studies using the Newcastle-Ottawa scale. Data were collected from cohort studies that compared overall survival, disease-free survival, and relapse-free survival between patients with high and patients with low expression of lncRNAs. Using 2,192 samples from 21 studies, we observed a correlation between poor prognosis and the upregulation of 14 lncRNAs (LINC00173, HUMT, HOTAIR, LUCAT1, HIF1A-AS2, ZEB2-AS1, NAMPT-AS, DANCR, LINC01638, ZNF469-3, AFAP1-AS1, ANRIL, MALAT1, and HULC) and downregulation of four lncRNAs (MIR503HG, NEF, TC0NS_12_00002973, and GAS5). The pooled hazard ratios for the correlation between differentially expressed lncRNAs and overall, disease-free, and relapse-free survival were 2.38 (2.03-2.78), 2.19 (1.51-3.16), and 3.19 (0.81-12.53), respectively. This meta-analysis shows that the expression of candidate lncRNAs may reliably predict the prognosis of patients with TNBC.

中文翻译：

---

LncRNA差异表达在三阴性乳腺癌中的预后价值：系统评价和荟萃分析。

乳腺癌是全世界女性中最常见的癌症，可以分为多种亚型，包括三阴性乳腺癌（TNBC）。TNBC比其他类型的乳腺癌更具侵略性，并且预后较差。但是，除化学疗法外，TNBC的治疗不涉及靶向治疗。lncRNA的表达失调在众多癌症的发展中起着至关重要的作用。因此，本荟萃分析的目的是确定lncRNA在TNBC中的功能作用。我们使用多个在线数据库（包括PubMed，EMBASE，Web of Science和Science-Direct）对与TNBC相关的文章进行了系统的搜索。我们整理了95％置信区间的合并危险比，以评估lncRNA的预后价值。我们使用纽卡斯尔-渥太华量表评估了研究质量。从队列研究中收集的数据比较了lncRNA高表达和低表达患者之间的总生存期，无病生存期和无复发生存期。使用来自21个研究的2,192个样本，我们观察到不良预后与14种lncRNA（LINC00173，HUMT，HOTAIR，LUCAT1，HIF1A-AS2，ZEB2-AS1，NAMPT-AS，DANCR，LINC01638，ZNF469-3，AFAP1 -AS1，ANRIL，MALAT1和HULC）和四个lncRNA（MIR503HG，NEF，TC0NS_12_00002973和GAS5）的下调。差异表达的lncRNA与总生存期，无疾病生存期和无复发生存期之间相关性的合并风险比分别为2.38（2.03-2.78），2.19（1.51-3.16）和3.19（0.81-12.53）。